Cardiovascular diseases (CVDs) are the clinical syndromes responsible for the highest death rate worldwide. Amongst them, heart failure is an ending stage of CVD, where blood pumping by the myocardium is severely reduced due in part to heart remodeling expressed as cardiac myocyte hypertrophy and cardiac fibrosis. It has been shown that Resveratrol, a polyphenol, can reduce hypertrophy in the cardiac myocytes. However, its therapeutic use is limited by low bioavailability and high metabolization rate. To this end, the use of polymeric nanoparticles (NPs) promotes a protected drug transport, avoiding such disadvantages, while offering a controlled and sustained release.  <br/> <br/><br/>The purpose of this work is to understand the new possible interactions between the use of a NPs to deliver Resveratrol into cardiac cells, and assess whether this route offers a better way to threat cardiac hypertrophy. Resveratrol was encapsulated by poly (D, L-lactic-co-glycolic acid). These NPs were functionalized with either chitosan (CS) or polyethylene glycol (PEG) to improve cell internalization and blood flow circulation time, respectively. The NPs were characterized and presented a mean diameter of 147.9 ± 59.68 and 191.5 ± 28.03 nm, and zeta potential of 6.32 ± 0.78 mV and -4.74 ± 1.43 mV for CS and PEG, respectively. The resveratrol entrapment efficiency was 61.35%. The FTIR spectrum were consistent with the structure of functionalized nanoparticles by covalent binding showing and amide band at 1646 cm-1. Functionalized NPs show no cytotoxicity at high NP cell doses (100 g/mL). Preliminary results show that PLGA-Resveratrol NPs can modulate hypertrophy the cardiac cells line H9c2.

Development of a platform for resveratrol delivery: Functionalization of resveratrol-loaded nanoparticles and hypertrophy modulation in cardiac cells

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.